Aldeyra Therapeutics Management
Management criteria checks 2/4
Aldeyra Therapeutics' CEO is Todd Brady, appointed in Jan 2012, has a tenure of 12.83 years. total yearly compensation is $3.68M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 1.94% of the company’s shares, worth $5.60M. The average tenure of the management team and the board of directors is 3.8 years and 11.3 years respectively.
Key information
Todd Brady
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 15.8% |
| CEO tenure | 12.8yrs |
| CEO ownership | 1.9% |
| Management average tenure | 3.8yrs |
| Board average tenure | 11.3yrs |
Recent management updates
Recent updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Jun 21
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap
Dec 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$38m |
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$4m | US$581k | -US$38m |
| Sep 30 2023 | n/a | n/a | -US$46m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$61m |
| Dec 31 2022 | US$3m | US$559k | -US$62m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$63m |
| Dec 31 2021 | US$3m | US$547k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$53m |
| Jun 30 2021 | n/a | n/a | -US$46m |
| Mar 31 2021 | n/a | n/a | -US$39m |
| Dec 31 2020 | US$2m | US$544k | -US$38m |
| Sep 30 2020 | n/a | n/a | -US$39m |
| Jun 30 2020 | n/a | n/a | -US$49m |
| Mar 31 2020 | n/a | n/a | -US$55m |
| Dec 31 2019 | US$4m | US$523k | -US$61m |
| Sep 30 2019 | n/a | n/a | -US$58m |
| Jun 30 2019 | n/a | n/a | -US$50m |
| Mar 31 2019 | n/a | n/a | -US$46m |
| Dec 31 2018 | US$3m | US$506k | -US$39m |
| Sep 30 2018 | n/a | n/a | -US$35m |
| Jun 30 2018 | n/a | n/a | -US$29m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$2m | US$473k | -US$22m |
Compensation vs Market: Todd's total compensation ($USD3.68M) is above average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: Todd's compensation has increased whilst the company is unprofitable.
CEO
Todd Brady (52 yo)
12.8yrs
Tenure
US$3,684,651
Compensation
Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 12.8yrs | US$3.68m | 1.94% $ 5.6m | |
| Chief Development Officer | 3.8yrs | US$1.59m | 0.19% $ 542.1k | |
| Principal Financial & Accounting Officer | less than a year | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Operations Manager | no data | no data | no data |
3.8yrs
Average Tenure
52yo
Average Age
Experienced Management: ALDX's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 19.8yrs | US$3.68m | 1.94% $ 5.6m | |
| Independent Chair of the Board | 8.2yrs | US$221.98k | 0.21% $ 606.3k | |
| Independent Director | 14.4yrs | US$190.40k | 0.047% $ 137.0k | |
| Independent Director | 15.5yrs | US$194.07k | 0.025% $ 71.8k | |
| Independent Director | 11.1yrs | US$195.66k | 0.040% $ 116.2k | |
| Independent Director | 11.4yrs | US$174.22k | 0.027% $ 76.9k | |
| Member of Retina Segment Scientific Advisory Board | no data | no data | no data | |
| Member of Anterior Segment Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Anterior Segment Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$174.22k | 0% $ 0 | |
| Member of Anterior Segment Scientific Advisory Board | no data | no data | no data | |
| Member of Anterior Segment Scientific Advisory Board | no data | no data | no data |
11.3yrs
Average Tenure
65yo
Average Age
Experienced Board: ALDX's board of directors are seasoned and experienced ( 11.3 years average tenure).